RecruitingNot Applicable

Long-term Safety and Effectiveness of Growtropin®-II Treatment in Children With Short Stature

South Korea2,500 participantsStarted 2021-02-08

Plain-language summary

This study evaluates long-term safety and effectiveness of Growtropin®-II treatment in children with short stature.

Who can participate

Age range2 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Children with short stature by growth hormone deficiency(GHD) or idiopathic short stature (ISS) or turner's syndrome(TS) or small for gestational age(SGA) * Children who has official height record at least 6 months prior Exclusion Criteria: * Children with Epiphyseal closure

What they're measuring

Long term safety assessed through the adverse events

Timeframe: Up to 2 years after epiphyseal closure

Trial details

NCT IDNCT04798690

SponsorDong-A ST Co., Ltd.

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2031-12

Contact for this trial

Sung

+82-2-920-8369 jhsung@donga.co.kr

View on ClinicalTrials.gov More Growth Hormone Deficiency trials